SCHEMBL18797486

SCHEMBL18797486

Fc1ccc(Cl)c(F)c1Br

nearest known ligand 0.33

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.32
SLC2A1 P11166 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31559780 0.79 CYP3A4 (0.35) TP53SLC2A1
SCHEMBL11131552 0.79 TP53 (0.32) TP53SLC2A1
SCHEMBL313506 0.77 CES2 (0.36)
SCHEMBL22162367 0.75 HTR2A (0.35)
SCHEMBL17744305 0.75 CYP3A4 (0.42)
SCHEMBL18894025 0.75 DPP4 (0.37) SLC2A1
SCHEMBL31483105 0.75 HTR2A (0.35)
SCHEMBL22124723 0.75
SCHEMBL22123573 0.75 NOTUM (0.39)
SCHEMBL31483102 0.75 HTR2A (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024111957-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE 삼성에스디아이 주식회사 2024-05-30 WO disclosed
WO-2024111957-A1 COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE 삼성에스디아이 주식회사 2024-05-30 WO disclosed
CN-114874209-A Oxadiazole transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2022-08-09 CN disclosed
EP-3368036-B1 MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS MERCK SHARP & DOHME LLC (US) 2022-07-20 EP disclosed
CN-110461838-B Oxadiazole transient receptor potential channel inhibitors 豪夫迈·罗氏有限公司 2022-05-06 CN disclosed
CN-108430471-B Factor XIa inhibitors 默沙东公司 2021-07-09 CN disclosed
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
US-20180339977-A1 FACTOR XIA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-11-29 US disclosed
EP-3368036-A1 FACTOR XIA INHIBITORS Merck Sharp & Dohme Corp. (US) 2018-09-05 EP disclosed
WO-2017074832-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 TP53 4121/4885SLC2A1 1911/4885
US-20180339977-A1 FACTOR XIA INHIBITORS F11, SERPINC1, TFPI TP53 4565/4885SLC2A1 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.